COLOGNE, Germany--(BUSINESS WIRE)--The USPTO approved a patent for Axiogenesis AG for the invention of its in vitro assay to screen pharmaceutical drug candidates for effectiveness and safety in ...

Sigma Life Science signed an agreement with Axiogenesis to market mouse induced pluripotent stem (iPS) cell-derived cardiomyocytes and smooth muscle cells, enabling long-term studies to accurately ...

Axiogenesis claims that its Cor.At murine ESC-derived cardiomyocytes represent the first physiologically relevant disease model of cardiomyopathy. Lonza negotiated exclusive, worldwide rights to ...

GOSSELIES,Belgium & COLOGNE, Germany & LEIDEN, Netherlands & PHILADELPHIA--(BUSINESS WIRE)--Ncardia (www.ncardia.com) has been established following the merger of Pluriomics and Axiogenesis. The ...

Axiogenesis AG, a leading global provider of in vitro models of healthy and diseased human cell types derived from induced pluripotent stem cells (iPSC), announced today that they have joined the ...

The United States Patent and Trademark Office (USPTO) has granted patent for Axiogenesis AG for the invention of its in vitro assay to screen pharmaceutical drug candidates for effectiveness and ...

Roche and Axiogenesis AG have announced that they have entered into an agreement for the development and distribution for Axiogenesis’ Cor.At® 100% pure cardiomyocytes platform as an integral part of ...

Axiogenesis AG and Metrion Biosciences Ltd have signed a collaboration agreement to validate, optimise and commercialise iPSC-derived cell based assays to facilitate drug discovery and more accurately ...

Sigma Life Science, the biological products and services arm of Sigma-Aldrich Corporation (SIAL), announced a deal with Axiogenesis to launch mouse induced pluripotent stem (iPS) cell-derived ...

COLOGNE, Germany--(BUSINESS WIRE)--Axiogenesis AG and iPS Academia Japan Inc. (Kyoto, Japan) announced that they have executed a non-exclusive agreement with iPS Academia (Kyoto, Japan) through which ...

Axiogenesis AG, a leading supplier of tissue-specific human cell types derived from induced pluripotent stem cells (iPSCs), and provider of pre-clinical drug development assays and disease models, ...

Sigma Life Science, the biological products and services arm of Sigma-Aldrich Corporation ( SIAL), announced a deal with Axiogenesis to launch mouse induced pluripotent stem (iPS) cell-derived ...